# Vivasure Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivasure-medical

- Industry: Medical Devices & Equipment
- Headquarters: Galway, Ireland
- Website: www.vivasuremedical.com
- Total disclosed funding: $66M
- Latest round: Series D (May 11, 2022)
- Investors on record: 12

## About

Based in Ireland, Vivasure Medical Ltd. specializes in advanced polymer implants for minimally invasive vessel closure in cardiology and vascular surgery, enhancing patient outcomes with innovative solutions.Vivasure Medical Ltd. is a medical device company focused on developing advanced closure solutions for vascular procedures. Founded in 2009 and headquartered in Galway, Ireland, the company has engaged in 10 deals to date. Its most recent funding round was a Series D, raising EUR 30.00 mn from Haemonetics Corporation, bringing the total amount raised to EUR 30.00 mn. The CEO of the company is Andrew Glass.Vivasure Medical specializes in advanced polymer implants and delivery systems for minimally invasive vessel closure in cardiology, interventional radiology, and vascular surgery. The flagship product, PerQseal, is a fully synthetic absorbable implant for managing arteriotomies up to 24F, featuring automatic loading and safety mechanisms. The product's next-generation version, PerQseal+, offers seamless deployment without sutures or metal components, catering to healthcare providers across Europe.For the most recent year, Vivasure Medical reported revenue of EUR 65,922.40 and an EBITDA of EUR 1,949,409.70. The company operates on a direct-to-business model, supplying innovative closure devices to hospitals and medical institutions, generating revenue primarily through product sales to healthcare providers.Vivasure Medical plans to utilize the recent funding for product development and market expansion. The company is focused on launching new versions of its products and entering new geographic regions to enhance its presence. Specific future markets have not been detailed, but the funding will support strategic initiatives aimed at increasing adoption of its innovative medical devices.

## Funding rounds

- Series D, May 11, 2022, $22M — Fountain Healthcare Partners, Panakes Partners, Evonik Venture Capital, Abiomed, Inc., Orchestra BioMed, Inc., Haemonetics Corporation, LSP Health Economics Fund, Enterprise Ireland
- Series C, Apr 12, 2018, $6.7M — Fountain Healthcare Partners, Western Development Commission, Panakes Partners, Evonik Venture Capital, Orchestra BioMed, Inc., LSP Health Economics Fund
- Series C, Aug 18, 2016, $13M — EQT Life Sciences, Ascent Biomedical Ventures, Fountain Healthcare Partners, Western Development Commission, Panakes Partners, Evonik Venture Capital, Enterprise Ireland
- Series B, Jul 22, 2014, $7.5M — Ascent Biomedical Ventures, Orchestra Medical Ventures, Fountain Healthcare Partners, Western Development Commission, Enterprise Ireland
- Series A, Jan 30, 2012, $6.8M — Ascent Biomedical Ventures, Orchestra Medical Ventures, Fountain Healthcare Partners, Western Development Commission, Enterprise Ireland
- Series A, Sep 18, 2009, $9.6M — Ascent Biomedical Ventures, Orchestra Medical Ventures, Fountain Healthcare Partners, Western Development Commission, Enterprise Ireland

## Investors

- Ascent Biomedical Ventures (https://capitalatlas.ai/funds/ascent-biomedical-ventures) — Series A, Series B, Series C
- Orchestra Medical Ventures (https://capitalatlas.ai/funds/orchestra-medical-ventures) — Series A, Series B
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series A, Series B, Series C, Series D
- Western Development Commission (https://capitalatlas.ai/funds/western-development-commission) — Series A, Series B, Series C
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Series A, Series B, Series C, Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series C
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series C, Series D
- Evonik Venture Capital (https://capitalatlas.ai/funds/evonik-venture-capital) — Series C, Series D
- Orchestra BioMed, Inc. — Series C, Series D
- LSP Health Economics Fund — Series C, Series D
- Abiomed, Inc. — Series D
- Haemonetics Corporation — Series D